Anti-VEGFR3 (Vascular Endothelial Growth Factor Receptor 3, VEGFR-3, Fms-like Tyrosine Kinase 4, FLT-4, Tyrosine-protein Kinase Receptor FLT4, FLT4) Polyclonal Antibody

Cat# V2110-20P-100ul

Size : 100ul

Brand : US Biological

Request more information

Contact local distributor :


Phone : +1 850 650 7790


V2110-20P VEGFR3 (Vascular Endothelial Growth Factor Receptor 3, VEGFR-3, Fms-like Tyrosine Kinase 4, FLT-4, Tyrosine-protein Kinase Receptor FLT4, FLT4)

Clone Type
Polyclonal
Host
rabbit
Source
human
Isotype
IgG1
Grade
Affinity Purified
Applications
E WB
Crossreactivity
Hu
Shipping Temp
Blue Ice
Storage Temp
-20°C

Embryonic vascular system undergoes a series of complex, highly regulated series of events involving differentiation, migration and association of primitive endothelial cells. This process is termed vasculogenesis. A further remodeling of the primitive vascular system forms the mature cardiovascular system. This process is known as angiogenesis (sprouting of new capillary vessels from pre-existing vasculature). Study of tumor angiogenesis has led to the identification of several proteins including basic fibroblast growth factor (bFGF) and vascular endothelial growth factor. VEGF acts by interacting with a family of largely endothelial-specific receptor tyrosine kinases that includes VEGFR-1 (flt-1/flk-2), VEGFR-2 (flk- 1/KDR), and VEGFR-3/Flt-4. Disruption of VEGFRs interferes with differentiation of endothelial cells and it is lethal for the embryo. FLT-4 (mouse 1363aa and human 1298aa), a receptor protein tyrosine kinase, is a receptor for VEGF-C. Mouse FLT-4 protein topology: 1-24aa signal peptide, 25-1363 mature protein (25-775 EC domain, 776-797aa TM domain, 798-1363aa CP domain). FLT-4 is type 1 membrane protein. It is expressed in adult lung, and liver, and in fetal liver, brain, intestine, and placenta.

Applications:
Suitable for use in Western Blot, ELISA. Other applications not tested.

Recommended Dilution:
Western Blot: 1-10ug/ml (Chemiluminescence)
ELISA: 1:10,000-1:100,000; 50-100ng of control peptide/well
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O or PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Applications
Product Type: Pab|Isotype: IgG1|Host: rabbit|Source: human|Concentration: As reported|Form: Supplied as a lyophilized powder from PBS, 0.05% sodium azide.|Purity: Purified by immunoaffinity chromatography.|Immunogen: Synthetic peptide corresponding to 20aa of human FLT4, C-terminal, Cytoplasmic domain (KLH).|Specificity: Recognizes human FLT4.||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Immunogen
Synthetic peptide corresponding to 20aa of human FLT4, C-terminal, Cytoplasmic domain (KLH).
Form
Supplied as a lyophilized powder from PBS, 0.05% sodium azide.
Purity
Purified by immunoaffinity chromatography.
Specificity
Recognizes human FLT4.
References
1. Finnerty H et al (1993) Oncogene 8, 2293-2298. 2. Bailey SK et al 91992) Cancer Res. 52, 746-748. 3. Pajusola K et al (1992) Cancer Res. 52, 5738-5743. 4. Aprelikova O et al (1992) Cancer Res. 52, 746-748.